Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada

Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market

Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

Biocon names Peter Bains as Group CEO

Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect

Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh

The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field

Biocon Biologics announces leadership appointments

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

Biocon Biologics expands footprint in emerging markets

Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries

Biocon Biologics' Hulio Biosimilar to Humira now available in the US

The launch of HULIO in the United States is an important milestone for Biocon Biologics

Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments

For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)

Biocon Q3 FY23 revenue up 36%

The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses